IP Library Patent Application 17405543
Patent Application
App. No. 17/405,543

Ferric Organic Compounds, Uses Thereof and Methods of Making Same

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/405,543
Abstract

The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.

Claims (10)

1 - 81 . (canceled)

82 . A method of treating metabolic acidosis, comprising administering a therapeutically effective amount of an orally administrable form of ferric citrate to a subject, wherein the orally administrable form is prepared from a form of ferric citrate having a BET active surface area greater than 16 m 2 /g.

83 . The method of claim 82 , wherein the BET active surface area ranges from 16 m 2 /g. to 20 m 2 /g.

84 . The method of claim 82 , wherein the orally administrable form is selected from a tablet, a powder, a capsule and a granule.

85 . The method of claim 84 , wherein the orally administrable form is a tablet.

86 . The method of claim 82 , wherein the therapeutically effective amount is about 3 to 6 grams per day.

87 . The method of claim 82 , wherein the therapeutically effective amount is selected from 3 grams per day and 4.5 grams per day.

88 . The method of claim 82 , wherein the therapeutically effective amount is 3 grams per day.

89 . The method of claim 82 , wherein the therapeutically effective amount is 6 grams per day.

90 . The method of claim 82 , wherein the subject is a human being.

Assignments (8)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jun 25, 2024
From: BIOPHARMA CREDIT PLC
To: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 067839/0134 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 29, 2024
From: BIOPHARMA CREDIT PLC
To: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 066377/0741 →
FIFTEENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 4, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 066205/0143 →
THIRTEENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 29, 2023
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063189/0065 →
TWELFTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 29, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 062012/0561 →
ELEVENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 22, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 061297/0238 →
TENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 16, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 060529/0168 →
SECURITY INTEREST Recorded Dec 15, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058399/0055 →